3-(2-fluoro-4,5-dimethoxyphenyl)propanoic acid | 881190-38-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(2-fluoro-4,5-dimethoxyphenyl)propanoic acid
• 英文别名: 3-(2-Fluoro-4,5-dimethoxyphenyl)propanoic acid
• CAS: 881190-38-1
• 化学式: C₁₁H₁₃FO₄
• 分子量: 228.22
• InChiKey: AQWWLTBHXDGWFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(2-fluoro-4,5-dimethoxyphenyl)propanoic acid 、 2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)aniline 在 chloro-N,N,N',N'-bis(tetramethylene)formamidinium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以57%的产率得到N-(2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-3-(2-fluoro-4,5-dimethoxyphenyl)propanamide
  参考文献：
  名称：

  Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu₇ Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962)

  摘要：

  Herein, we report the discovery of a new, orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (mGlu(7)) negative allosteric modulator (NAM) that achieves exposure in cerebral spinal fluid (CSF) 2.5x above the in vitro IC50 at minimum effective doses (MEDs) of 3 mg/kg in preclinical anxiety models.

  DOI：

  10.1021/acs.jmedchem.8b01810
• 作为产物：
  描述：

  6-氟藜芦醛 在 sodium tetrahydroborate 、 palladium 10% on activated carbon 作用下， 以 二氯甲烷 、 溶剂黄146 、 甲苯 为溶剂， 反应 17.0h， 生成 3-(2-fluoro-4,5-dimethoxyphenyl)propanoic acid
  参考文献：
  名称：

  Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu₇ Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962)

  摘要：

  Herein, we report the discovery of a new, orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (mGlu(7)) negative allosteric modulator (NAM) that achieves exposure in cerebral spinal fluid (CSF) 2.5x above the in vitro IC50 at minimum effective doses (MEDs) of 3 mg/kg in preclinical anxiety models.

  DOI：

  10.1021/acs.jmedchem.8b01810

文献信息

• Cyclic amine derivative or salt thereof
  申请人：Hayashibe Satoshi

  公开号：US20070197594A1

  公开（公告）日：2007-08-23

  Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro- 1 H-cyclopenta[1]naphthalene) via X 1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.

  提供的化合物是NMDA受体拮抗剂，具有广泛的安全边界，并可用作治疗或预防阿尔茨海默病、脑血管性痴呆、帕金森病、缺血性卒中、疼痛等药物。具体提供的是胺衍生物或其盐，其特点在于其中含有胺基结构A，通过X1（键或低碳烷基）与2-或3-环状紧缩环（例如茚烷、四氢萘酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-茚并[4,5-b]呋喃、2,3-二氢-1H-环戊[1]萘烷）结合；以及含有它作为有效成分的NMDA受体拮抗剂。
• CYCLIC AMINE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP1795524A1

  公开（公告）日：2007-06-13

  Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro-1H-cyclopenta[1]naphthalene) via X1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.

  本发明提供的化合物是一种具有广泛安全范围的 NMDA 拮抗剂，可作为阿尔茨海默病、脑血管痴呆症、帕金森病、缺血性脑中风、疼痛等的治疗剂或预防剂。具体而言，提供了一种胺衍生物或其盐，其特征在于其中的含胺结构 A 与 2-或 3-环缩合环（如茚满、四烯酮、4-环缩合环、5-环缩合环、6-环缩合环、7-环缩合环、8-环缩合环、9-环缩合环）结合、茚、四酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-茚并[4,5-b]呋喃、2,3-二氢-1H-环戊并[1]萘）通过 X1（键或低级亚烷基）结合；以及含有它作为其活性成分的 NMDA 拮抗剂。
• Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu₇ Negative Allosteric Modulator (NAM) in Vivo Tool Compound: <i>N</i>-(2-(1<i>H</i>-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962)
  作者：Carson W. Reed、Samantha E. Yohn、Jordan P. Washecheck、Hanna F. Roenfanz、Marc C. Quitalig、Vincent B. Luscombe、Matthew T. Jenkins、Alice L. Rodriguez、Darren W. Engers、Anna L. Blobaum、P. Jeffrey Conn、Colleen M. Niswender、Craig W. Lindsley

  DOI：10.1021/acs.jmedchem.8b01810

  日期：2019.2.14

  Herein, we report the discovery of a new, orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (mGlu(7)) negative allosteric modulator (NAM) that achieves exposure in cerebral spinal fluid (CSF) 2.5x above the in vitro IC50 at minimum effective doses (MEDs) of 3 mg/kg in preclinical anxiety models.